Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing.

Kelly A JohnsonXin NiuDavid V GliddenJose R Castillo-MancillaJenna YagerSamantha MaWhinneyMary MorrowHideaki OkochiTim R CresseyPaul K DrainMonica GandhiPeter L AndersonMatthew A Spinelli

Published in: Open forum infectious diseases (2021)

From directly observed therapy studies, urine tenofovir (TFV) levels were 74% lower when taking tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate. Urine TFV remains quantifiable across a range of TAF adherence patterns, but a separate point-of-care lateral flow immunoassay with a lower TFV threshold will be needed to support TAF adherence monitoring.

Keyphrases

antiretroviral therapy
adipose tissue
stem cells
type diabetes
metabolic syndrome
glycemic control
bone marrow
sensitive detection
quantum dots